PCI Pharma Services, a global CDMO, has announced the construction of a Clinical Center of Excellence in Bridgewater, Massachusetts, providing clinical storage, distribution and packaging services to meet growing New England clinical supply market demands. The major investment will allow the company to be closer to its clients in the tri-state area and engage with more than a thousand additional clients in Boston/Cambridge.
This news follows the company’s recent announcement it has signed a definitive agreement to acquire LSNE, a CDMO in New Hampshire.
“The biotech and pharmaceutical industries have been rapidly expanding in the Northeast, especially Boston, in the last few years, and this new Clinical Center of Excellence and our recent definitive agreement to acquire LSNE, will create more convenience and efficiencies for our Northeast clients by offering them a center that combines a local feel and global capabilities,” said Brian Keesee, VP and General Manager, Global Operations and Supply of Clinical Services, PCI Pharma Services. “This expansion is part of our larger strategy to serve biopharmaceutical clients by providing a facility that can service their needs within a relatively short driving distance, while adding to our global footprint.”
The 50,000 sqft centre is currently under construction with an expected completion of Summer 2022. Throughout the last 18 months, the company has invested in global clinical sites including San Diego, Rockford, Melbourne and Berlin as part of its global clinical expansion in all services. This includes investing in additional facilities, refrigerators and freezers, increasing capacity, and adding storage conditions in service to both large and small molecule compounds.
“Our decentralised global offering that features several smaller hubs around the world is a key reason why we’re a leader in the clinical trials space,” said Salim Haffar, CEO, PCI Pharma Services. “This centre will localise PCI’s global capabilities in the Boston area, providing our Northeast clients with critical services to facilitate the packaging and distribution of life-changing treatments.”
